Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia

G. Gürman, H. Çelebi, C. Üstün, M. Arat, O. Ilhan, M. Özcan, Ö Arslan, A. Uysal, H. Akan, M. Beksaç, N. Konuk, H. Koç

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Allogeneic peripheral blood stem cell transplantation- (PBSCT) is rarely applied for the treatment of severe aplastic anemia (SAA) because of questionable durability of engraftment and increased risk of graft versus host disease (GVHD). We performed allogeneic PBSCT in 3 SAA patients from their human leukocyte antigen (HLA)-identical siblings. One received bone marrow after conditioning with cyclophoshamide (Cy) plus antithymocyte globulin. He had a second transplant with peripheral blood stem cells from the original donor because of a graft failure (GF). Two other patients received PBSCT as a first option, with Cy as the only conditioning drug. The 3 patients received short-term methotrexate and cyclosporine as a postgrafting immunosupression. In the latter 2 cases, no GF has been observed, and a successful and complete hematological recovery was achieved and maintained for 28 and 25 months, respectively. In conclusion, PBSCT provides a quick and complete hematological recovery in SAA patients.

Original languageEnglish (US)
Pages (from-to)54-57
Number of pages4
JournalTherapeutic Apheresis
Issue number1
StatePublished - 2001


  • Allogeneic peripheral blood stem cell transplantation
  • Severe aplastic anemia


Dive into the research topics of 'Allogeneic peripheral blood stem cell transplantation for severe aplastic anemia'. Together they form a unique fingerprint.

Cite this